Since alterations in the NF2 gene are the most common genetic abnormality in meningiomas and occur more frequently in aggressive meningiomas [42,43,44], these findings suggest that the loss of merlin/NF2 promotes the development and progression of meningiomas through the functional inactivation of the p53 pathway, which provides support for the therapeutic targeting of wild-type p53 in aggressive meningiomas. This evidence concerns the gene TP53 and meningioma.